Noviets Pharma vs. Novartis: Delhi HC Upholds Injunction

Background & Material Facts

Want to learn the fundamentals of Trademark Law? Read our complete Trademark Law Guide.

The dispute in Noviets Pharma & Ors. Vs. Novartis AG & Ors. (FAO(OS) (COMM)-143/2026) centers on a trademark infringement and passing off action initiated by the respondents, Novartis AG and others. The appellants, Noviets Pharma, were restrained from using the mark “NOVIETS” following an ad-interim injunction granted by a learned Single Judge of the Delhi High Court. The respondents asserted their rights over the mark “NOVARTIS,” a global pharmaceutical entity. The core of the respondents’ case rested on their established reputation, prior usage, and the claim that the appellants’ mark “NOVIETS” was deceptively similar to their own, likely to cause confusion in the marketplace among consumers of pharmaceutical products.

The appellants challenged the injunction, arguing that their usage of “NOVIETS” was in the capacity of a business identifier rather than as a trademark for specific goods. Furthermore, the appellants pointed to correspondence between the respondents and the Trade Marks Registry to suggest that the respondents’ claims were weakened by their own procedural history. The respondents countered by highlighting their robust portfolio of registrations across multiple classes and their status as a prior user of the “NOVARTIS” mark. They emphasized that “NOVARTIS” is a well-known mark, recognized as such in various WIPO and INDRP proceedings, thereby warranting high-level protection against dilution and infringement.

Legal Issues

The appellate bench was tasked with determining whether the learned Single Judge exercised judicial discretion appropriately when granting the ad-interim injunction. The primary legal questions included:

• Whether “NOVIETS” satisfies the criteria for deceptive similarity under Section 29 of the Trade Marks Act, 1999 (the Act, which governs the registration of trademarks and provides remedies for infringement).
• Whether the appellants’ use of “NOVIETS” as a business identifier provides a valid defense against an infringement or passing off claim.
• Whether the balance of convenience and the potential for irreparable harm justified the grant of temporary injunctive relief.
• Whether the respondents, as holders of a well-known mark, established a strong prima facie case of triple identity involving similarity in name, class, and market presence.

Court’s Reasoning & Findings

The Division Bench of the Delhi High Court upheld the decision of the learned Single Judge. The Court affirmed that the standard of deceptive similarity under Section 29 of the Act was met. In evaluating the marks, the Court noted that the phonetic and visual similarity between “NOVARTIS” and “NOVIETS” was significant enough to deceive the average consumer, particularly in the sensitive pharmaceutical sector where precision is paramount. The Court found that the appellants’ arguments regarding their use of the mark as a business identifier were insufficient to defeat an infringement claim. It maintained that using a confusingly similar mark, even in a different capacity, does not insulate a party from liability for passing off.

The Court placed heavy weight on the evidence that “NOVARTIS” has been declared a well-known mark. The inclusion of the mark in international proceedings, such as those governed by WIPO (the World Intellectual Property Organization, which manages global intellectual property systems) and INDRP (the Indian Domain Name Dispute Resolution Policy, which governs disputes over .in domain names), bolstered the respondents’ position. These international and domestic acknowledgments reinforced that the mark possesses a high degree of distinctiveness and goodwill.

Regarding the appellants’ argument concerning the respondents’ correspondence with the Trade Marks Registry, the Court held that such procedural interactions did not extinguish the respondents’ substantive rights to prevent third-party infringement. The Court observed that the respondents’ prior user status and extensive registration portfolio were clear. Consequently, the finding of a strong prima facie case was substantiated by the “triple identity” present in the matter, referring to the alignment of the mark’s sound, the nature of the business, and the consumer base.

Furthermore, the Court addressed the criteria for interim relief. It concluded that the learned Single Judge had correctly applied the settled principles of law regarding the balance of convenience. Given the strength of the respondents’ case and the risk of irreparable harm to their brand reputation if the infringement were allowed to continue, the grant of an ad-interim injunction was deemed both necessary and proportionate. The appellants failed to demonstrate that the lower court had acted on a perverse or incorrect interpretation of the facts or the law.

Also Read: Calcutta HC Returns ITC Plaint for Skipping Section 12A Mediation

Decision & Significance

The Division Bench dismissed the appeal, confirming the temporary injunction against the appellants. The judgment underscores several key principles for IP practitioners:

• Phonetic Similarity in Pharmaceuticals: The Court reiterated that even slight phonetic variations in pharmaceutical marks are scrutinized strictly to prevent consumer confusion, which could have public health implications.
• Well-Known Mark Status: The reliance on WIPO and INDRP findings serves as a reminder that courts will readily consider international recognition when assessing the strength of a mark, even if the primary cause of action is domestic.
• Business Identifier Defense: The decision clarifies that adopting a mark as a business name or identifier provides no immunity from trademark infringement claims if that name is deceptively similar to a pre-existing, well-known mark.
• Interim Relief Threshold: The Court reaffirmed that where a plaintiff can demonstrate a strong prima facie case and a clear risk of irreparable harm, the judiciary will favor the protection of established intellectual property rights over the business interests of an infringer.

This ruling serves as a vital affirmation of the rigorous standards applied to protect marks with established global reputation. By rejecting the appellants’ technical arguments and focusing on the underlying potential for deception and the proprietary rights of the respondents, the Delhi High Court has clarified the boundaries for businesses operating in the pharmaceutical sector. Practitioners should note the consistency with which the Court upholds the rights of well-known mark holders against entities attempting to ride on the coattails of established corporate identities.